Selecta Biosciences Appoints Peter Keller as Vice President of Business Development and Alliance Management

Selecta Biosciences Appoints Peter Keller as Vice President of Business Development and Alliance Management

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, announced today that Peter Keller, M. Sci., has been appointed as Vice President of Business Development and Alliance Management. Mr. Keller brings more than 15 years of experience as a pharmaceutical executive and leader. He will report directly to Werner Cautreels, Ph.D., Chief Executive Officer of Selecta Biosciences.

"We are extremely pleased that Peter will be joining our team in leading Selecta's business development activities"
."We are extremely pleased that Peter will be joining our team in leading Selecta's business development activities," said Werner Cautreels, Ph.D., Chief Executive Officer of Selecta Biosciences. "Advancing our partnering discussions and business alliances is central to leveraging the vast potential of Selecta's product platforms."

Selecta's proprietary breakthrough technology creates a new paradigm in vaccine development, enabling completely new therapeutic applications with improved efficacy and safety profiles.

"The diversity of Selecta's unique Synthetic Vaccine Particle (SVPTM) platform enables us to address a wide range of diseases including cancer, autoimmune diseases, allergies, infectious diseases and neuroscience," said Mr. Keller. "In addition to rapidly advancing our pipeline, we look forward to partnering with the world's leading biopharmaceutical companies in developing next-generation therapeutic and prophylactic vaccines."

Prior to joining Selecta, Mr. Keller was with Abbott Laboratories, where he led the integration process for the R&D and Manufacturing facilities in Europe following the acquisition of Solvay Pharmaceuticals in February 2010. Before that, Mr. Keller was Vice President and Head of M&A and Alliance Management for Solvay Pharmaceuticals. At Solvay, Mr. Keller negotiated license and acquisition agreements in various therapeutic areas such as vaccines, neurology and cardiology. He was the lead negotiator for the $1.5 billion fenofibrate alliance between Solvay Pharmaceuticals and Abbott Laboratories. Prior to joining Solvay, Mr. Keller spent ten years in management consulting; first with Simon Kucher and Partners and later with McKinsey & Company where he quickly rose to the position of Associate Principal. Over the years, Mr. Keller has worked with most of the largest pharmaceutical companies. His areas of expertise include marketing strategy and M&A transactions. Mr. Keller holds a Master's Degree in Industrial Engineering and Management from the University of Karlsruhe, Germany.

About Selecta

Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's proprietary Synthetic Vaccine Particle (SVPTM) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles. Selecta's fully synthetic engineering of novel vaccines offers a number of compelling benefits, including flexible modular vaccine design and accelerated development timelines using simplified manufacturing processes.

Selecta's SVPTM platform technology is flexible to enable diverse vaccines and the company has created targeted antigen-specific Synthetic Vaccine Particles (tSVPTM) and targeted antigen-specific tolerogenic Synthetic Vaccine Particles (t2SVPTM). Targeted Synthetic Vaccine Particles (tSVPTM) activate immune responses to a wide array of relevant antigens, including small molecules, peptides, oligosaccharides, and proteins. These particles can target humoral or cellular pathways of the immune system. Examples for applications include cancer, infectious diseases and addiction. Targeted tolerogenic Synthetic Vaccine Particles (t2SVPTM) are designed to induce antigen-specific immune tolerance. Examples for applications include autoimmune diseases, allergies and transplant rejection. Building on the company's novel approach, Selecta's product candidates have the potential to become first-in-class or best-in-class therapeutics to treat and prevent diseases.

Selecta Biosciences is based in Watertown, Massachusetts, USA. For more information, please visit www.selectabio.com.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.